Harvard Bioscience (HBIO) EGM 2026 summary
Event summary combining transcript, slides, and related documents.
EGM 2026 summary
7 May, 2026Opening remarks and agenda
The meeting was called to order by the chairman, who welcomed stockholders and outlined the agenda and voting procedures.
Only stockholders of record as of January 21, 2026, or holders of a valid proxy, were entitled to vote.
Specific resolutions to be voted on
Proposal 1: Approve an amendment to the Certificate of Incorporation to effect a reverse stock split at a ratio between 1-for-5 and 1-for-15, at the board's discretion.
Proposal 2: Approve adjournment or postponement of the meeting, if necessary, to solicit additional votes for Proposal 1.
Corporate governance
Broadridge Financial Solutions was appointed as Inspector of Election, with an oath of impartiality filed.
A quorum was confirmed, with a majority of voting power present or represented by proxy.
Latest events from Harvard Bioscience
- Gross margin rose to 59% as revenue fell, with stable EBITDA and cost-saving initiatives underway.HBIO
Q1 202612 May 2026 - Strategic focus, operational streamlining, and innovation drive growth and recurring revenue.HBIO
Investor presentation12 May 2026 - Margins improved and 2026 guidance targets growth from new products and operational discipline.HBIO
Q4 202528 Apr 2026 - Key votes include director elections, auditor ratification, and equity plan share increases.HBIO
Proxy filing22 Apr 2026 - Shareholders will vote on director elections, auditor ratification, executive pay, and equity plan amendments.HBIO
Proxy filing22 Apr 2026 - Strategic focus, innovation, and operational efficiency drive margin and recurring revenue growth.HBIO
2026 KeyBanc Capital Markets Healthcare Forum20 Mar 2026 - Q2 2024 revenue fell nearly 20% with net loss widening, prompting reduced full-year guidance.HBIO
Q2 20242 Feb 2026 - Growth driven by new organoid and bioproduction systems, with APAC recovery boosting outlook.HBIO
Jefferies Global Healthcare Conference1 Feb 2026 - Shareholders to vote on a reverse stock split to maintain Nasdaq listing and flexibility.HBIO
Proxy Filing30 Jan 2026